The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).
 
Elizabeth Catherine Smyth
Employment - HCA International (I)
Honoraria - Bristol-Meyer Squibb; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Serono; Novartis; Roche; SERVIER; Zymeworks
Research Funding - Bristol-Meyers Squibb (Inst)
 
Joseph Chao
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo; Foundation Medicine; Geneos; Lilly; Macrogenics; Merck; Novartis; Ono Pharmaceutical; Roche; Silverback Therapeutics; Turning Point Therapeutics
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Foundation Medicine; Macrogenics; Merck
Other Relationship - Yiviva
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical
 
Priscilla Yen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Rolando Eduardo Yanes
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Anita Zahlten-Kumeli
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; LG Chem; MSD Oncology
Speakers' Bureau - BMS/Ono; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen